Federal Circuit Revisits Myriad Breast Cancer Gene Claims
WASHINGTON – It was an encore performance in the Federal Circuit Friday as the panel of judges that ruled on the Association for Molecular Pathology v. Myriad Genetics Inc. last year listened to pretty much the same arguments about the patentability of isolated DNA all over again.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter